Author details

Full Name

Hu Li

Affiliation

ORCID

Career Start Year

2013

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37982822	Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3Î² Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies.	Clin Cancer Res	2024
37193683	Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era.	Blood Cancer J	2023
37371475	SPIN-AI: A Deep Learning Model That Identifies Spatially Predictive Genes.		2023
34600126	Manifold medicine: A schema that expands treatment dimensionality.	Drug Discov Today	2022
35832612	Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma.	Computational and Structural Biotechnology Journal	2022
35764649	Senescent cells limit p53 activity via multiple mechanisms to remain viable.	Nature Communications	2022
34911739	NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy.	Cancer Immunol Res	2022
34876496	De novo individualized disease modules reveal the synthetic penetrance of genes and inform personalized treatment regimens.	Genome Research	2022
33875655	Transcriptomic analysis to identify genes associated with selective hippocampal vulnerability in Alzheimer's disease.	Nat Commun	2021
33524942	Synthetic and systems biology principles in the design of programmable oncolytic virus immunotherapies for glioblastoma.	Neurosurgical Focus	2021
34950182	Associations of Serum Tumor Biomarkers with Integrated Genomic and Clinical Characteristics of Hepatocellular Carcinoma.	Liver Cancer	2021
34746803	Senescent cells suppress innate smooth muscle cell repair functions in atherosclerosis.	Nature Aging	2021
34709885	p21 produces a bioactive secretome that places stressed cells under immunosurveillance.	Science	2021
34045642	Modular network mechanism of CCN1-associated resistance to HSV-1-derived oncolytic immunovirotherapies for glioblastomas.	Scientific Reports	2021
31738183	BubR1 allelic effects drive phenotypic heterogeneity in mosaic-variegated aneuploidy progeria syndrome.	Journal of Clinical Investigation	2020
31053471	PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy.	Molecular Cell	2019
29950863	lncRNA H19 predicts poor prognosis in patients with melanoma and regulates cell growth, invasion, migration and epithelial-mesenchymal transition in melanoma cells.	OncoTargets and Therapy	2018
25833694	Down-regulation of miR-489 contributes into NSCLC cell invasion through targeting SUZ12.	Tumor Biology	2015
23031786	Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer.	Experimental and Molecular Pathology	2013
23343082	Selection and characterization of human anti-MAGE-A1 scFv and immunotoxin.	Anti-Cancer Agents in Medicinal Chemistry	2013